{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,2,29]],"date-time":"2024-02-29T23:01:47Z","timestamp":1709247707996},"reference-count":71,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2009,6,1]],"date-time":"2009-06-01T00:00:00Z","timestamp":1243814400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2009,6,1]],"date-time":"2009-06-01T00:00:00Z","timestamp":1243814400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin J Gastroenterol"],"published-print":{"date-parts":[[2009,6]]},"DOI":"10.1007\/s12328-009-0089-5","type":"journal-article","created":{"date-parts":[[2009,6,1]],"date-time":"2009-06-01T01:09:20Z","timestamp":1243818560000},"page":"149-155","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Thalidomide: an emerging drug in oral mucosal lesions"],"prefix":"10.1007","volume":"2","author":[{"given":"K.","family":"Mubeen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. Ahmed","family":"Siddiq","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V. R.","family":"Jigna","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2009,6,2]]},"reference":[{"key":"89_CR1","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1016\/0030-4220(91)90273-F","volume":"71","author":"LA MacPhail","year":"1991","unstructured":"MacPhail LA, Greenspan D, Feigal DW, Lennette ET, Greenspan JS. Recurrent aphthous ulcers in association with HIV infection: description of ulcer types and analysis of T-lymphocyte subsets. Oral Surg Oral Med Oral Pathol. 1991;71:678\u201383.","journal-title":"Oral Surg Oral Med Oral Pathol"},{"key":"89_CR2","first-page":"827","volume":"134","author":"IJ Buno","year":"1998","unstructured":"Buno IJ, Huff JC, Weston WL, Cook DT, Brice SL. Elevated levels of interferon gamma, tumor necrosis factor \u03b1, interleukins 2, 4, and 5, but not interleukin 10, are present in recurrent aphthous stomatitis. Arch Dermatol. 1998;134:827\u201331.","journal-title":"Arch Dermatol"},{"key":"89_CR3","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1001\/archderm.1979.04010050060027","volume":"115","author":"JM Mascaro","year":"1979","unstructured":"Mascaro JM, Lecha M, Torras H. Thalidomide in the treatment of recurrent, necrotic, and giant mucocutaneous aphthae and aphthosis. Arch Dermatol. 1979;115:636\u20137.","journal-title":"Arch Dermatol"},{"key":"89_CR4","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1001\/archderm.1982.01650230003002","volume":"118","author":"H Torras","year":"1982","unstructured":"Torras H, Lecha M, Mascaro JM. Thalidomide treatment of recurrent necrotic giant mucocutaneous aphthae and aphthosis. Arch Dermatol. 1982;118:875.","journal-title":"Arch Dermatol"},{"key":"89_CR5","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1136\/bmj.287.6395.799","volume":"287","author":"PW Bowers","year":"1983","unstructured":"Bowers PW, Powell RJ. Effect of thalidomide on orogenital ulceration. BMJ. 1983;287:799\u2013800.","journal-title":"BMJ"},{"key":"89_CR6","doi-asserted-by":"publisher","first-page":"1424","DOI":"10.1016\/S0140-6736(84)91622-2","volume":"2","author":"JS Jenkins","year":"1984","unstructured":"Jenkins JS, Powell RJ, Allen BR, Littlewood SM, Maurice PDL, Smith NJ. Thalidomide in severe orogenital ulceration. Lancet. 1984;2:1424\u20136.","journal-title":"Lancet"},{"key":"89_CR7","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/S0190-9622(85)70014-X","volume":"12","author":"D Grinspan","year":"1985","unstructured":"Grinspan D. Significant response of oral aphthosis to thalidomide treatment. J Am Acad Dermatol. 1985;12:85\u201390.","journal-title":"J Am Acad Dermatol"},{"key":"89_CR8","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1111\/j.1365-2133.1985.tb15281.x","volume":"112","author":"N Kurkcuoglu","year":"1985","unstructured":"Kurkcuoglu N, Atakan N, Eksioglu M. Thalidomide in the treatment of recurrent necrotic mucocutaneous aphthae. Br J Dermatol. 1985;112:632.","journal-title":"Br J Dermatol"},{"key":"89_CR9","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1001\/archderm.1990.01670310085012","volume":"126","author":"J Revuz","year":"1990","unstructured":"Revuz J, Guillaume JC, Janier M, Hans P, Marchand C, Souteyrand P, et al. Crossover study of thalidomide vs placebo in severe recurrent aphthous stomatitis. Arch Dermatol. 1990;126:923\u20137.","journal-title":"Arch Dermatol"},{"key":"89_CR10","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1084\/jem.173.3.699","volume":"173","author":"EP Sampaio","year":"1991","unstructured":"Sampaio EP, Sarno EN, Galilly R, Cohn ZA, Kaplan G. Thalidomide selectively inhibits tumour necrosis factor production by stimulated human monocytes. J Exp Med. 1991;173:699\u2013703.","journal-title":"J Exp Med"},{"key":"89_CR11","doi-asserted-by":"publisher","first-page":"1675","DOI":"10.1084\/jem.177.6.1675","volume":"177","author":"AL Moreira","year":"1993","unstructured":"Moreira AL, Sampaio EP, Zmuidzinas A, Frindt P, Smith KA, Kaplan G. Thalidomide exerts its inhibitory action on tumour necrosis factor by enhancing mRNA degradation. J Exp Med. 1993;177:1675\u201380.","journal-title":"J Exp Med"},{"key":"89_CR12","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1007\/BF00406421","volume":"269","author":"M Faure","year":"1980","unstructured":"Faure M, Thivolet J, Gaucherand M. Inhibition of polymorphonuclear leukocyte chemotaxis by thalidomide. Arch Dermatol Res. 1980;269:275\u201380.","journal-title":"Arch Dermatol Res"},{"key":"89_CR13","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1016\/S0190-9622(84)80458-2","volume":"11","author":"RL Barnhill","year":"1984","unstructured":"Barnhill RL, Doll NJ, Millikan LE, Hastings RC. Studies on the anti-inflammatory properties of thalidomide: Effects on polymorphonuclear leukocytes and monocytes. J Am Acad Dermatol. 1984;11:814\u20139.","journal-title":"J Am Acad Dermatol"},{"key":"89_CR14","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1086\/314842","volume":"180","author":"C Meierhofer","year":"1999","unstructured":"Meierhofer C, Dunzendorfer S, Wiedermann CJ. Protein kinase C-dependent effects on leukocyte migration of thalidomide. J Infect Dis. 1999;180:216\u20139.","journal-title":"J Infect Dis"},{"key":"89_CR15","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1111\/j.1365-2249.1995.tb05527.x","volume":"99","author":"SM McHugh","year":"1995","unstructured":"McHugh SM, Rifkin IR, Deighton J, Wilson AB, Lachlan PJ, Lockwood CM, et al. The immunosuppressive drug thalidomide induces T helper cell type 2 (Th2) and concomitantly inhibits Th1 cytokine production in mitogen and antigen stimulated human peripheral blood mononuclear cell cultures. Clin Exp Immunol. 1995;99:160\u20137.","journal-title":"Clin Exp Immunol"},{"key":"89_CR16","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1089\/088922299310269","volume":"15","author":"PA Haslett","year":"1999","unstructured":"Haslett PA, Klausner JD, Makonkawkeyoon S, Moreira A, Metatratip P, Boyle B, et al. Thalidomide stimulates T cell responses and interleukin 12 production in HIV-infected patients. AIDS Res Hum Retroviruses. 1999;15:1169\u201379.","journal-title":"AIDS Res Hum Retroviruses"},{"key":"89_CR17","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1086\/315328","volume":"181","author":"LG Bekker","year":"2000","unstructured":"Bekker LG, Haslett P, Maartens G, Steyn L, Kaplan G. Thalidomide-induced antigen-specific immune stimulation in patients with human immunodeficiency virus type 1 and tuberculosis. J Infect Dis. 2000;181:954\u201365.","journal-title":"J Infect Dis"},{"key":"89_CR18","doi-asserted-by":"publisher","first-page":"1885","DOI":"10.1084\/jem.187.11.1885","volume":"187","author":"PA Haslett","year":"1998","unstructured":"Haslett PA, Corral LG, Albert M, Kaplan G. Thalidomide costimulates primary human T lymphocytes, preferentially inducing proliferation, cytokine production and cytotoxic responses in the CD\u00a0+\u00a0subsets. J Exp Med. 1998;187:1885\u201392.","journal-title":"J Exp Med"},{"key":"89_CR19","first-page":"388","volume":"109","author":"MC Bach","year":"1988","unstructured":"Bach MC, Valenti AJ, Howell DA, Smith TJ. Odynophagia from aphthous ulcers of the pharynx and esophagus in the acquired immunodeficiency syndrome (AIDS). Ann Intern Med. 1988;109:388\u20139.","journal-title":"Ann Intern Med"},{"key":"89_CR20","doi-asserted-by":"publisher","first-page":"465","DOI":"10.7326\/0003-4819-76-3-112-6-465","volume":"112","author":"MC Bach","year":"1990","unstructured":"Bach MC, Howell DA, Valenti AJ, Smith TJ, Winslow DL. Aphthous ulceration of the gastrointestinal tract in patients with acquired immunodeficiency syndrome(AIDS). Ann Int Med. 1990;112:465\u20137.","journal-title":"Ann Int Med"},{"key":"89_CR21","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/0030-4220(94)90271-2","volume":"77","author":"BC Muzyka","year":"1994","unstructured":"Muzyka BC, Glick M. Major aphthous ulcers in patients with HIV disease. Oral Surg Oral Med Oral Pathol. 1994;77:116\u201320.","journal-title":"Oral Surg Oral Med Oral Pathol"},{"key":"89_CR22","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1136\/bmj.298.6671.432","volume":"298","author":"M Youle","year":"1989","unstructured":"Youle M, Clarbour J, Farthing C, Connolly M, Hawkins D, Staughton R, et al. Treatment of resistant aphthous ulceration with thalidomide in patients positive for HIV antibody. BMJ. 1989;298:432.","journal-title":"BMJ"},{"key":"89_CR23","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1016\/0140-6736(90)91223-W","volume":"335","author":"I Gorin","year":"1990","unstructured":"Gorin I, Vilette B, Gehanno P, Escande JP. Thalidomide in hyperalgic pharyngeal ulceration of AIDS. Lancet. 1990;335:1343.","journal-title":"Lancet"},{"key":"89_CR24","doi-asserted-by":"crossref","first-page":"382","DOI":"10.5694\/j.1326-5377.1990.tb125225.x","volume":"152","author":"PR Georghiou","year":"1990","unstructured":"Georghiou PR, Kemp RJ. HIV-associated esophageal ulcers treated with thalidomide. Med J Aust. 1990;152:382\u20133.","journal-title":"Med J Aust"},{"key":"89_CR25","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1056\/NEJM199207163270319","volume":"327","author":"J Ryan","year":"1992","unstructured":"Ryan J, Colman J, Pedersen J. Thalidomide to treat esophageal ulcer in AIDS. N Engl J Med. 1992;327:208\u20139.","journal-title":"N Engl J Med"},{"key":"89_CR26","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1016\/S0190-9622(08)81115-2","volume":"23","author":"B Radeff","year":"1990","unstructured":"Radeff B, Kuffer R, Samson J. Recurrent aphthous ulcer in patient infected with human immunodeficiency virus: successful treatment with thalidomide. J Am Acad Dermatol. 1990;23:523\u20135.","journal-title":"J Am Acad Dermatol"},{"key":"89_CR27","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1093\/clinids\/20.2.250","volume":"20","author":"DL Paterson","year":"1995","unstructured":"Paterson DL, Georghiou PR, Allworth AM, Kemp RJ. Thalidomide as treatment of refractory aphthous ulceration related to human immunodeficiency virus infection. Clin Infect Dis. 1995;20:250\u20134.","journal-title":"Clin Infect Dis"},{"key":"89_CR28","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.1056\/NEJM199705223362103","volume":"336","author":"JM Jacobson","year":"1997","unstructured":"Jacobson JM, Greenspan JS, Spritzler J, Ketter N, Fahey JL, Jackson JB, et al. Thalidomide for the treatment of oral aphthous ulcers in patients with human immunodeficiency virus infection. N Engl J Med. 1997;336:1487\u201393.","journal-title":"N Engl J Med"},{"key":"89_CR29","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1086\/314834","volume":"180","author":"JM Jacobson","year":"1999","unstructured":"Jacobson JM, Spritzler J, Fox L, Fahey JL, Jackson JB, Chernoff M, et al. Thalidomide for the treatment of esophageal aphthous ulcers in patients with Human Immunodeficiency Virus infection. J Infect Dis. 1999;180:61\u20137.","journal-title":"J Infect Dis"},{"key":"89_CR30","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1073\/pnas.87.2.782","volume":"87","author":"G Poli","year":"1990","unstructured":"Poli G, Kinter A, Justement JS. Tumor necrosis factor a functions in an autocrine manner in the induction of human immunodeficiency virus expression. Proc Natl Acad Sci USA. 1990;87:782\u20135.","journal-title":"Proc Natl Acad Sci USA"},{"key":"89_CR31","doi-asserted-by":"publisher","first-page":"5974","DOI":"10.1073\/pnas.90.13.5974","volume":"90","author":"S Makonkawkeyoon","year":"1993","unstructured":"Makonkawkeyoon S, Rhona NR, Pobre L, Moreira AL, Schauf V, Kaplan G. Thalidomide inhibits the replication of Human immunodefienceny virus type 1. Proc Natl Acad Sci. 1993;90:5974\u20138.","journal-title":"Proc Natl Acad Sci"},{"key":"89_CR32","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1146\/annurev.immunol.17.1.657","volume":"17","author":"EA Berger","year":"1999","unstructured":"Berger EA, Murphy PM, Faber JM. Chemokine receptor as HIV-1 coreceptors roles in viral entry, trophism and disease. Annu Rev Immunol. 1999;17:657\u2013700.","journal-title":"Annu Rev Immunol"},{"key":"89_CR33","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1086\/315478","volume":"181","author":"NP Juffermans","year":"2000","unstructured":"Juffermans NP, Verbon A, Olszyna DP, van Deventer SJ, Spleenman P, van der Poll T. Thalidomide suppresses up-regulation of human immunodeficiency virus coreceptors CXCR4 and CCR5 on CD4+ T cells in humans. J Infect Dis. 2000;181:1813\u20136.","journal-title":"J Infect Dis"},{"key":"89_CR34","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1007\/s00234-003-1102-1","volume":"45","author":"G Akman-Demir","year":"2003","unstructured":"Akman-Demir G, Bahar S, Coban O, Tasci B, Serdaroglu P. Cranial MRI in Beh\u00e7et\u2019s disease: 134 examinations of 98 patients. Neuroradiology. 2003;45:851\u20139.","journal-title":"Neuroradiology"},{"key":"89_CR35","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1097\/00002281-199901000-00009","volume":"1","author":"H Yazici","year":"1999","unstructured":"Yazici H, Yurdakul S, Hamuryudan V. Beh\u00e7et\u2019s syndrome. Curr opin Rhematol. 1999;1:53\u20137.","journal-title":"Curr Opin Rhematol"},{"key":"89_CR36","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1007\/BF03259272","volume":"3","author":"H Yazici","year":"1995","unstructured":"Yazici H, Yurdakul S, Hamuryudan V. Beh\u00e7et\u2019s syndrome. How should we treat it? Clin Immunother. 1995;3:102\u20137.","journal-title":"Clin Immunother"},{"key":"89_CR37","doi-asserted-by":"publisher","first-page":"493","DOI":"10.7326\/0003-4819-126-6-199703150-00021","volume":"126","author":"M Arici","year":"1997","unstructured":"Arici M, Kiraz S, Erteneli I. Treatment of Beh\u00e7et disease with pentoxifylline. Ann Intern Med. 1997;126:493\u20134.","journal-title":"Ann Intern Med"},{"key":"89_CR38","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1136\/ard.53.12.828","volume":"53","author":"JMM Gardner-Medwin","year":"1994","unstructured":"Gardner-Medwin JMM, Smith NJ, Powell RJ. Clinical experience with thalidomide in the management of severe oral and genital ulceration in conditions such as BehSet\u2019s disease: use of neurophysiological studies to detect thalidomide neuropathy. Ann Rheum Dis. 1994;53:828\u201332.","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"89_CR39","doi-asserted-by":"publisher","first-page":"443","DOI":"10.7326\/0003-4819-128-6-199803150-00004","volume":"128","author":"V Hamuryudan","year":"1998","unstructured":"Hamuryudan V, Mat C, Saip S, Ozyazgan Y, Aksel Siva, Yurdakul S, et al. Thalidomide in the treatment of the mucocutaneous lesions of the Beh\u00e7et syndrome: a randomized, double-blind, placebo-controlled trial. Ann Int Med. 1998;128(6):443\u201350.","journal-title":"Ann Int Med"},{"key":"89_CR40","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1542\/peds.103.6.1295","volume":"103","author":"LP Shek","year":"1999","unstructured":"Shek LP, Lee YS, Lee BW, Lehman TJ. Thalidomide responsiveness in an infant with Beh\u00e7et\u2019s syndrome. Pediatrics. 1999;103:1295\u20137.","journal-title":"Pediatrics"},{"key":"89_CR41","unstructured":"Denman AM, Graham E, Howe L, Denman EJ, Lightman S. Low dose of thalidomide treatment of Beh\u00e7et\u2019s syndrome. In: Wechsler B, Godeau P, editors. Beh\u00e7et\u2019s disease. Proceedings of the 6th International conference on Beh\u00e7et\u2019s disease, 30 June\u20131 July 1993; Paris, France, Amsterdam: Excerpta Medica; 1993. p. 649\u201353."},{"key":"89_CR42","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/S0022-3476(87)80285-8","volume":"110","author":"GS Marshall","year":"1987","unstructured":"Marshall GS, Edwards KM, Butler J, Lawton AR. Syndrome of periodic fever, pharyngitis, and aphthous stomatitis. J Pediatr. 1987;110:43\u20136.","journal-title":"J Pediatr"},{"key":"89_CR43","first-page":"186","volume":"8","author":"HM Feder Jr","year":"1989","unstructured":"Feder HM Jr. Periodic fever associated with aphthous stomatitis, pharyngitis and cervical adenitis. Pediatr Infect Dis J. 1989;8:186\u20137.","journal-title":"Pediatr Infect Dis J"},{"key":"89_CR44","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1055\/s-2002-34450","volume":"81","author":"GJ Ridder","year":"2002","unstructured":"Ridder GJ, Fradis M, Berner R, Lohle E. PFAPA syndrome: current standard of knowledge and relevance for the ENT specialist. Laryngorhinootologie. 2002;81:635\u20139.","journal-title":"Laryngorhinootologie"},{"key":"89_CR45","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1177\/000348940311200412","volume":"112","author":"M Berlucchi","year":"2003","unstructured":"Berlucchi M, Meini A, Plebani A, Bonvini MG, Lombardi D, Nicolai P. Update on treatment of Marshall\u2019s syndrome (PFAPA syndrome): report of five cases with review of the literature. Ann Otol Rhinol Laryngol. 2003;112:365\u20139.","journal-title":"Ann Otol Rhinol Laryngol"},{"key":"89_CR46","doi-asserted-by":"crossref","unstructured":"Marque M, Guillot B, Bessi Ds, Thalidomide for treatment of PFAPA syndrome (Letter). Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2007;103:306\u20137.","DOI":"10.1016\/j.tripleo.2006.10.011"},{"key":"89_CR47","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1111\/j.1365-4362.1985.tb05400.x","volume":"24","author":"B Naafs","year":"1985","unstructured":"Naafs B, Faber WR. Thalidomide therapy: an open trial. Int J Dermatol. 1985;24:131\u20134.","journal-title":"Int J Dermatol"},{"key":"89_CR48","doi-asserted-by":"publisher","first-page":"1392","DOI":"10.1001\/archderm.1996.03890350136031","volume":"132","author":"O Dereure","year":"1996","unstructured":"Dereure O, Basset-Seguin N, Guilhou J. Erosive lichen planus: dramatic response to thalidomide. Arch Dermatol. 1996;132:1392\u20133.","journal-title":"Arch Dermatol"},{"key":"89_CR49","doi-asserted-by":"publisher","first-page":"1442","DOI":"10.1001\/archderm.136.12.1442","volume":"136","author":"C Camisa","year":"2000","unstructured":"Camisa C, Popovsky JL. Effective treatment of oral erosive lichen planus with thalidomide. Arch Dermatol. 2000;136:1442\u20133.","journal-title":"Arch Dermatol"},{"key":"89_CR50","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1046\/j.1523-1747.1999.00744.x","volume":"113","author":"MR Nasca","year":"1999","unstructured":"Nasca MR, O\u2019toole EA, Palicharla P, West DP, Woodley DT. Thalidomide increases human keratinocyte migration and proliferation. J Invest Dermatol. 1999;113:720\u20134.","journal-title":"J Invest Dermatol"},{"key":"89_CR51","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1056\/NEJM197108122850711","volume":"285","author":"J Folkman","year":"1971","unstructured":"Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med. 1971;285:1182\u20136.","journal-title":"N Engl J Med"},{"key":"89_CR52","doi-asserted-by":"publisher","first-page":"1827","DOI":"10.1016\/S0006-2952(98)00046-X","volume":"55","author":"KS Bauer","year":"1998","unstructured":"Bauer KS, Dixon SC, Figg WD. Inhibition of angiogenesis by thalidomide requires metabolic activation, which is species dependent. Biochem Pharmacol. 1998;55:1827\u201334.","journal-title":"Biochem Pharmacol"},{"key":"89_CR53","doi-asserted-by":"publisher","first-page":"4082","DOI":"10.1073\/pnas.91.9.4082","volume":"91","author":"RJ D\u2019Amato","year":"1994","unstructured":"D\u2019Amato RJ, Loughnan MS, Flynn E, Folkman J. Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci USA. 1994;91:4082\u20135.","journal-title":"Proc Natl Acad Sci USA"},{"key":"89_CR54","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1006\/exer.1997.0292","volume":"64","author":"BM Kenyon","year":"1997","unstructured":"Kenyon BM, Browne F, D\u2019Amato RJ. Effects of thalidomide and related metabolites in a mouse corneal model of neovascularization. Exp Eye Res. 1997;64:971\u20138.","journal-title":"Exp Eye Res"},{"key":"89_CR55","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1038\/nature04479","volume":"438","author":"L Coultas","year":"2005","unstructured":"Coultas L, Chawengsaksophak K, Rossant J. Endothelial cells and VEGF in vascular development. Nature. 2005;438:937\u201345.","journal-title":"Nature"},{"key":"89_CR56","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1248\/bpb.25.597","volume":"25","author":"MG Marks","year":"2002","unstructured":"Marks MG, Shi J, Fry MO, Xiao FZ, Trzyna M, Pokala V, et al. Effects of putative hydroxylated thalidomide metabolites on blood vessel density in the chorioallantoic membrane (CAM) assay and on tumor and endothelial cell proliferation. Biol Pharm Bull. 2002;25:597\u2013604.","journal-title":"Biol Pharm Bull"},{"key":"89_CR57","first-page":"364","volume":"342","author":"S Singhal","year":"2000","unstructured":"Singhal S, Mehta J, Desikan R, Ayers D, Roberson P, Eddlemon P et al. Antitumor activity of thalidomide in refractory multiple myeloma (published correction appears in N Engl J Med. 2000;342:364). N Engl J Med 1999;341:1565\u201371.","journal-title":"N Engl J Med"},{"key":"89_CR58","doi-asserted-by":"publisher","first-page":"897","DOI":"10.4065\/75.9.897","volume":"75","author":"SV Rajkumar","year":"2000","unstructured":"Rajkumar SV, Fonseca R, Dispenzieri A, Lacy MQ, Lust JA, Witzig TE, et al. Thalidomide in the treatment of relapsed multiple myeloma. Mayo Clin Proc. 2000;75:897\u2013901.","journal-title":"Mayo Clin Proc"},{"key":"89_CR59","doi-asserted-by":"publisher","first-page":"34","DOI":"10.4065\/78.1.34","volume":"78","author":"S Kumar","year":"2003","unstructured":"Kumar S, Gertz MA, Dispenzieri A, Lacy MQ, Geyer SM, Iturria NL, et al. Response rate, durability of response, and survival after thalidomide therapy for relapsed multiple myeloma. Mayo Clin Proc. 2003;78:34\u20139.","journal-title":"Mayo Clin Proc"},{"key":"89_CR60","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1038\/sj.leu.2402866","volume":"17","author":"SV Rajkumar","year":"2003","unstructured":"Rajkumar SV, Gertz MA, Lacy MQ, Dispenzieri A, Fonseca R, Geyer SM, et al. Thalidomide as initial therapy for early-stage myeloma. Leukemia. 2003;17:775\u20139.","journal-title":"Leukemia"},{"key":"89_CR61","doi-asserted-by":"publisher","first-page":"2593","DOI":"10.1200\/JCO.2000.18.13.2593","volume":"18","author":"RF Little","year":"2000","unstructured":"Little RF, Wyvill KM, Pluda JM, Welles L, Marshall V, Figg WD, et al. Activity of thalidomide in AIDS-related Kaposi\u2019s sarcoma. J Clin Oncol. 2000;18:2593\u2013602.","journal-title":"J Clin Oncol"},{"key":"89_CR62","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1159\/000106583","volume":"215","author":"P Rubegni","year":"2007","unstructured":"Rubegni P, Sbano P, De Aloe G, Flori ML, Fimiani M. Thalidomide in the Treatment of Kaposi\u2019s Sarcoma. Dermatology. 2007;215:240\u20134.","journal-title":"Dermatology"},{"key":"89_CR63","first-page":"222","volume":"5","author":"A Viejo-Borbolla","year":"2003","unstructured":"Viejo-Borbolla A. Schultz TF: Kaposi\u2019s sarcoma-associated herpesvirus (KSHV\/HHV8): key aspects of epidemiology and pathogenesis. AIDS Rev. 2003;5:222\u20139.","journal-title":"AIDS Rev"},{"key":"89_CR64","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1128\/JCM.36.8.2220-2222.1998","volume":"36","author":"JC Mendez","year":"1998","unstructured":"Mendez JC, Procop GW, Espy MJ, Paya CV. Smith TF: Detection and semiquantitative analysis of human herpesvirus 8 DNA in specimens from patients with Kaposi\u2019s sarcoma. J Clin Microbiol. 1998;36:2220\u20132.","journal-title":"J Clin Microbiol"},{"key":"89_CR65","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1258\/0956462981921512","volume":"9","author":"K Fife","year":"1998","unstructured":"Fife K, Howard MR, Bower M, Gracie F. Activity of thalidomide in AIDS-related Kaposi\u2019s sarcoma and correlation with HHV8 titre. Int J STD AIDS. 1998;9:751\u20135.","journal-title":"Int J STD AIDS"},{"key":"89_CR66","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1111\/j.1572-0241.2006.00350.x","volume":"101","author":"L Milazzo","year":"2006","unstructured":"Milazzo L, Biasin M, Gatti N, Piacentini L, Niero F, Zanone Poma B, et al. Thalidomide in the treatment of chronic hepatitis C unresponsive to \u03b1-interferon and ribavirin. Am J Gastroenterol. 2006;101:399\u2013402.","journal-title":"Am J Gastroenterol"},{"key":"89_CR67","doi-asserted-by":"publisher","first-page":"116","DOI":"10.2165\/00002018-199207020-00004","volume":"7","author":"V Gunzler","year":"1992","unstructured":"Gunzler V. Thalidomide in human immunodeficiency virus (HIV) patients: a review of safety considerations. Drug Saf. 1992;7:116\u201334.","journal-title":"Drug Saf"},{"key":"89_CR68","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1046\/j.1523-1747.2002.19502.x","volume":"119","author":"S Bastuji-Garin","year":"2002","unstructured":"Bastuji-Garin S, Ochonisky S, Bouche P, Gherardi RK, Duguet C, Djerradine Z, et al. Thalidomide Neuropathy Study Group. Incidence and risk factors for thalidomide neuropathy: a prospective study of 135 dermatologic patients. J Invest Dermatol. 2002;119:1020\u20136.","journal-title":"J Invest Dermatol"},{"key":"89_CR69","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1016\/S0190-9622(96)90122-X","volume":"35","author":"S Tseng","year":"1996","unstructured":"Tseng S, Pak G, Washenik K, Pomeranz MK, Shupack JL. Rediscovering thalidomide: a review of its mechanism of action, side effects, and potential uses. J Am Acad Dermatol. 1996;35:969\u201379.","journal-title":"J Am Acad Dermatol"},{"key":"89_CR70","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/S1085-5629(98)80019-9","volume":"17","author":"DI Stirling","year":"1998","unstructured":"Stirling DI. Thalidomide and its impact in dermatology. Semin Cutan Med Surg. 1998;17:231\u201342.","journal-title":"Semin Cutan Med Surg"},{"key":"89_CR71","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1111\/j.1365-2133.2005.06747.x","volume":"153","author":"JJ Wu","year":"2005","unstructured":"Wu JJ, Huang DB, Pang KR, Hsu S, Tyring SK. Thalidomide: dermatological indications, mechanisms of action and side-effects. Br J Dermatol. 2005;153:254\u201373.","journal-title":"Br J Dermatol"}],"container-title":["Clinical Journal of Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12328-009-0089-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12328-009-0089-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12328-009-0089-5","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12328-009-0089-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,29]],"date-time":"2022-07-29T12:40:19Z","timestamp":1659098419000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12328-009-0089-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,6]]},"references-count":71,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2009,6]]}},"alternative-id":["89"],"URL":"https:\/\/doi.org\/10.1007\/s12328-009-0089-5","relation":{},"ISSN":["1865-7257","1865-7265"],"issn-type":[{"value":"1865-7257","type":"print"},{"value":"1865-7265","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,6]]},"assertion":[{"value":"26 March 2009","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 April 2009","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 June 2009","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}